People
Maja Ludvigsen, Associate Professor
With a background in molecular biology and a PhD in health sciences, I lead a research group fueled by a strong passion for translational cancer research with a special focus on hematological malignancies.
My work spans the full spectrum of cancer cell characterization: from molecular biology and tumor microenvironment studies to large‑scale proteomics, imaging flow cytometry, and the development of novel gene‑editing therapies.
By integrating these approaches, my goal is to turn complex biological insights into real, clinically meaningful diagnostics and treatments for patients with urgent, unmet medical needs.
Carina Rosenberg, PhD, MSc, Senior Researcher
Department of Clinical Medicine - Hematology
carirose@rm.dk
I work as Senior Researcher in HemeLab, hold a PhD from the Faculty of Health from Aarhus University and am a graduate of Biology also from Aarhus University.
I have a fundamental interest in flow cytometry and in HemeLab I have implemented the imaging flow cytometry methodology and strive to demonstrate the diagnostic potential of the technique in the complex field of hematology.
I lead our projects on how imaging flow cytometry can be used to rethink diagnostics in myelodysplastic syndrome and acute myeloid leukemia by employing morphometric evaluation of neoplastic cells.
Mette Richner, PhD, MSc, Senior Researcher
Department of Clinical Medicine - Hematology
mettrc@rm.dk
I hold a PhD in neuroscience from Health, Aarhus University. With a strong background in molecular biology, drug testing and animal studies, I’m always happy to contribute wherever my expertise is needed.
I also enjoy supervising students in our group and taking part in their projects — supporting their ideas, encouraging curiosity, and helping them grow as young scientists.
Marie Hairing Enemark, PhD, MSc, Postdoc
Department of Clinical Medicine - Hematology
mariem@rm.dk
I have a PhD-degree from Health, Aarhus University. With a background in Molecular Medicine my work focuses on transformation of follicular lymphoma. This event is analyzed through molecular biological methods and clinicopathological data, including proteomics, immunohistochemistry and more. In addition, I enjoy supervising students in our group and getting involved in their projects as well.
Johannes Frasez Sørensen, MD, PhD student
Department of Clinical Medicine - Hematology
johasr@rm.dk
I have a background as a medical doctor from Aarhus University.
My PhD project addresses acute myeloid leukemia (AML), focusing on in vivo delivery of CRISPR-Cas9 using lipid nanoparticles as a candidate vector. The long-term scope of the project is novel therapy for patients with AML.
Katharina Wolter, MSc, PhD Student
Department of Clinical Medicine - Hematology
kawolt@rm.dk
My name is Katharina, and I have a Master’s degree in Molecular Medicine from Aarhus University. I started my PhD in March 2024.
I am working on developing a novel gene therapy for fusion-driven childhood acute leukemia using CRISPR-Cas9.
Trine Engelbrecht Hybel, MSc, PhD Student
Department of Clinical Medicine - Hematology
trihyb@rm.dk
My name is Trine. I am a PhD student in HemeLab and have a Master’s degree in molecular medicine from Aarhus University.
My project focuses on evaluating dysplasia in myeloid hematological malignancies using a combination of artificial intelligence and imaging flow cytometry. So far, I have focused on assessing the applicability of this technique to distinguish healthy and leukemic stem cells from acute myeloid leukemia patients. In addition, I am also involved in research concerning lymphoma in immunosuppressed patients, which has included various analyses such as immunohistochemistry and next-generation sequencing.
Daniel Kjær Andersen, MSc, PhD Student
Department of Clinical Medicine - Hematology
daiane@rm.dk
Cecilie Dohrmann, MSc, PhD Student
Department of Clinical Medicine - Hematology
cecdoh@rm.dk
With a background in Molecular Medicine from Aarhus University, I am now pursuing my integrated PhD.
My project dives into the molecular landscape of follicular lymphoma patients, aiming to unravel what drives their histological transformation. Ultimately, I hope to pinpoint biomarkers that can sharpen patient‑specific risk stratification. To get there, I am putting a range of tools to work: from immunohistochemistry to imaging mass cytometry and beyond.
Sofie Bundsbæk Mouridsen, MSc, PhD Student
Department of Clinical Medicine - Hematology
somour@rm.dk
I hold an MSc in Molecular Medicine from Aarhus University and am now a PhD student in HemeLab.
I joined the team in February 2024 and dove straight into my project: delivering CRISPR‑Cas9 in vivo using lipid nanoparticles. My mission? To outsmart AML with the t(8;21) translocation and help pave the way for a brand‑new gene‑editing therapy.
Naja Svinth Lorenzen, MSc, Research Assistant
Department of Clinical Medicine - Hematology
nalore@rm.dk
I earned my Master’s degree in Molecular Medicine from Aarhus University here in HemeLab and now continue as a Research Assistant.
My project uses Imaging Flow Cytometry (IFC) to spot dysplasia in patients with myelodysplastic syndrome (MDS). The long‑term goal? Sharpen MDS diagnostics by combining Imaging Flow Cytometry (IFC) with AI‑driven image classification to detect dysplasia with far greater precision.
Caroline Stengaard Jensen, BSc, Master's Student
Molecular Medicine
caromj@rm.dk
My name is Caroline, and I am pursuing a Master’s degree in Molecular Medicine at Aarhus University.
My project focuses on follicular lymphoma (FL), where I investigate protein biomarkers linked to early disease progression (POD24). Through proteomics analysis and bioinformatics, I aim to identify key markers that can improve early risk assessment. Significant findings will be validated using immunohistochemistry to enhance clinical relevance.
Freja Lundberg, BSc, Master's Student
Molecular Medicine
frejln@rm.dk
My name is Freja, and I am currently doing a MSc in Molecular Medicine at Aarhus University. I joined the lab in January 2025 where I am working on a project focusing on in vivo delivery of CRISPR-Cas9 using lipid nanoparticles as delivery vectors. This project aims to develop targeted gene-editing therapies for acute myeloid leukemia (AML) patients with the t(8;21) translocation, with the goal of establishing this as a novel therapy for AML.
Nithiyaa Karunakaran, BSc, Master's Student
Molecular Medicine
nikaru@rm.dk
My name is Nithiyaa, and I study Molecular Medicine at Aarhus University. In February 2025, I joined the laboratory to conduct my Molecular Medicine Research Project.
My research focuses on gene therapy targeting the t(9;11) translocation associated with acute myeloid leukemia (AML). This approach uses CRISPR-Cas9-based gene editing, where electroporation and lipid nanoparticles are employed to deliver Cas9 and guide RNA to leukemia cell lines.
Jette Sloth Glerup, BSc, Master's Student
Molecular Biology
jetgle@rm.dk
I am a Master’s student in Molecular Biology currently working on my Master’s thesis in the HemeLab group, which I joined in September 2025.
My project focuses on developing a CRISPR/Cas9-based treatment for fusion-protein–driven sarcoma. Synovial sarcoma is caused by the chromosomal translocation t(X;18), which produces the oncogenic SS18-SSX fusion protein. By delivering CRISPR/Cas9 using lipid nanoparticles, I aim to achieve targeted disruption of the cancer-driving fusion gene.
Previous work in the HemeLab group has demonstrated that fusion-driven leukemia can be treated using a similar approach, and my goal is to extend this strategy to synovial sarcoma.
Jeanica Peter Gomes, BSc
Molecular Medicine
jeapeg@rm.dk
I am a MSc student in Molecular Medicine at Aarhus University.
I joined the group in January 2026 to conduct my Molecular Medicine Research Project, where I am part of a project focusing on optimizing the delivery of lipid nanoparticles(LNPs) containing CRISPR-Cas9 to leukemic myeloblasts. More specifically, I investigate whether conjugating specific antibodies to the LNPs can improve the transfection of leukemic myeloblasts, with the aim of developing a better treatment for acute myeloidleukemia (AML).
Christina Denvig Sigvardsen, BSc
Molecular Medicine
chsigv@rm.dk
I am a MSc student in Molecular Medicine at Aarhus University. In January 2026, I joined the group to conduct my Molecular Medicine Research Project.
My project is focusing on the in vivo delivery of CRISPR-Cas9 using lipid nano particles (LNPs) with the aim of developing a novel gene-editing strategy for AML carrying the t(8;21) translocation. Specifically, I investigate potential differences in LNP uptake between established cell lines and patient-derived cells.
Marie Kyndi Laursen, BSc
Molecular Medicine
makyla@rm.dk
I am working on my Master’s degree in Molecular Medicine at Aarhus University. I joined the lab in January 2026 to conduct my Molecular Medicine Research Project.
The project I am working on centres on the detection of surface markers on acute myeloid leukaemia (AML) cells using flow cytometry, to identify them as potential targets for CAR-T cell therapy.
Anne-Mie Dollerup Green, Administrative Support
The local secretary Anne-Mie Dollerup Green at Hematology Laboratory, Aarhus University Hospital, serves administrative issues for all staff and students connected to the research group.
Lab Alumni
Short-term Projects & Internships
2025
Iman Azzam
Tharsika Sureshkumar
Fanny Silke Jaeger Hansen, MSc, Trainee
Department of Clinical Medicine - Hematology
fanhan@rm.dk
I joined the lab in September 2024 and completed my Master’s in Molecular Biology from Aarhus University here in HemeLab. After a short break, I jumped back in as a trainee and am now optimizing and developing a SOP for a freezing procedure that preserves plasma for high‑quality proteomic analyses.
Maja Irene Dam Andersen, MD, PhD
MD, Ph.d.
Institut of Clinical Medicine - Hematology
maja.aner@auh.rm.dk
My name is Maja. I am a medical doctor specializing in hematology from Aarhus University. Since 2013, I have been part of the lymphoma research group, studying the microenvironment in Hodgkin lymphoma. I began my PhD-study in 2020, and have been using various molecular methods, such as proteomics, immunohistochemistry, and gene expression analyses to try to better understand the mechanism behind the disease. In addition to my research, I also mentor and supervise students in our group.
Sebastian Haunstrup Reimick, MSc
MSc
Molecular Biology
sebrei@rm.dk
My name is Sebastian. I am a MSc student in Molecular Biology at Aarhus University. Cancer research has always been my main interest, so I am thrilled to be involved in applied research projects with fusion-cancers in focus here at HemeLab. My current project is to investigate whether our CRISPR gene therapy technique can be utilized in fusion-sarcomas. More specifically synovial sarcoma which is characterized by translocation t(18;X). I have previously been involved in the acute myeloid leukemia with translocation t(8;21) project with Johannes Frasez Sørensen here in HemeLab. Besides working with in vivo CRISPR/Cas9 delivery in the AML project, I have also previously worked with delivery optimization of the Cas9 protein.
Melanie Kempf Hansen, MSc
Master's student
Molecular Biology
melahn@rm.dk
My name is Melanie. I am a MSc student in Molecular Biology at Aarhus University. I joined the lab in September 2024 and I am currently working on a project concerning a specific type of acute myeloid leukemia with the translocation t(8;21). The lab has previously shown with a proof-of-concept study that the translocation can be removed by gene editing therapy using CRISPR/Cas9 technology. My role in this project is to characterize cellular changes following gene therapy by utilizing transcriptomic and proteomics methods.
Signe Neldeborg, PhD
My name I Signe. I have a masters degree in Molecular Medicine from Aarhus University. I am currently finishing my PhD thesis on a CRISPR-Cas9-based treatment modality for fusion-driven cancer diseases. My main focus is on acute myeloid leukemia and non-small cell lung cancer.
Emma Frasez Sørensen, MSc
My name is Emma. I have a background in Molecular Medicine. Currently, I am working on an integrated PhD focusing on the development of measurable residual disease (MRD) assessment of AML patients. Previously, I completed my bachelor's thesis at the HemeLab where I investigated lymphomas arising in HIV and PTLD patients. My main supervisor is MD, PhD, Hans Beier Ommen, and Maja Ludvigsen is a co-supervisor on the project.
Maya Nautrup Pedersen, MSc
MSc Molecular Medicine
Institut of Clinical Medicine - Hematology
mayapd@rm.dk
My name is Maya. I am a molecular medicine master student, and I have a bachelor's degree in molecular medicine from Aarhus University. I joined Ludvigsen Lab in spring 2023, and during the spring I will be working on a research project investigating blood cells in the bone marrow. My project focuses on the megakaryopoiesis, and I will be using imaging flow cytometry to establish an assay and gating templates, which can be used to detect abnormally developed and matured megakaryocytes in bone marrow from patients with myelodysplastic syndrome (MDS).
Sofie Hesselberg Jensen, MSc
My name is Sofie. I am a Molecular Medicine Master Student doing my master’s thesis at Ludvigsens lab (2022-2023). My project focuses on measurable residual disease in acute myeloid leukemia (AML) and the aim is to investigate imaging flow cytometry as a tool for distinguishing healthy hematopoietic stem cells from leukemic stem cells in bone marrow from AML patients. This is done by training both traditional machine learning and deep learning algorithms, exploiting the morphometric parameters estimated from the IFC data.